Matthew Wleklinski
Last active: 9/5/2017


None provided


The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. Reprogramming cell fate with a genome-scale library of artificial transcription factors. Eguchi A, Wleklinski MJ, Spurgat MC, Heiderscheit EA, Kropornicka AS, Vu CK, Bhimsaria D, Swanson SA, Stewart R, Ramanathan P, Kamp TJ, Slukvin I, Thomson JA, Dutton JR, Ansari AZ (2016) Proc Natl Acad Sci U S A 113(51): E8257-E8266
    › Primary publication · 27930301 (PubMed) · PMC5187731 (PubMed Central)
  2. Nuclear epidermal growth factor receptor is a functional molecular target in triple-negative breast cancer. Brand TM, Iida M, Dunn EF, Luthar N, Kostopoulos KT, Corrigan KL, Wleklinski MJ, Yang D, Wisinski KB, Salgia R, Wheeler DL (2014) Mol Cancer Ther 13(5): 1356-68
    › Primary publication · 24634415 (PubMed) · PMC4013210 (PubMed Central)
  3. Mapping C-terminal transactivation domains of the nuclear HER family receptor tyrosine kinase HER3. Brand TM, Iida M, Luthar N, Wleklinski MJ, Starr MM, Wheeler DL (2013) PLoS One 8(8): e71518
    › Primary publication · 23951180 (PubMed) · PMC3738522 (PubMed Central)